ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
Performance of novel tau antibodies across multiple modalities for Alzheimer's disease assessment.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Region-resolved proteomic map of the human brain: functional interconnections and neurological implications.Signal transduction and targeted therapy · 2026Article
- Alzheimer's disease neuropathological characterization of the dog brain and relationship to biofluid biomarkers and cognitive function.NPJ dementia · 2026Article
- Performance of novel tau antibodies across multiple modalities for Alzheimer's disease assessment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
introductionEpitope-specific antibodies are crucial for accurately identifying pathologic forms of proteins like hyperphosphorylated tau in Alzheimer's disease (AD).
methodsWe developed monoclonal antibodies targeting phosphorylated tau (p-tau) at sites pT181, pT217, and pT231 using peptide immunogens. Antibody performance was assessed using peptide immunoprecipitation-mass spectrometry, western blot, and quantitative immunohistochemistry in brain, and single-molecule array immunoassay in cerebrospinal fluid (CSF).
resultsThese antibodies demonstrated specific immunoprecipitation of phosphorylated peptides in phosphate-buffered saline, CSF, and plasma. Quantitative immunostaining in brain tissue highlighted neuronal tau pathology and were negative in control tissues (P < 0.01 for mice; P < 0.001 for humans). Western blotting with recombinant p-tau and post mortem AD brain tissue samples provided further validation. In a pilot CSF immunoassay these antibodies performed similarly to commercial antibodies (R DISCUSSION: Overall, our work contributes new reagents for AD research, specifically anti-p-tau antibodies, for the scientific community. HIGHLIGHTS: Novel phosphorylated tau pT181, pT217, and pT231 antibodies are sensitive and specific. The antibodies perform well across multiple modalities for diagnosis and research. The cerebrospinal fluid assay with these antibodies is similar to a commercial assay (Quanterix). The antibodies are freely accessible from the Developmental Studies Hybridoma Bank.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.